Usage summary
Strongest role: Inclusion Required
Inclusion-required count: 23
Treatment-assignment count: 0
Stratification count: 0
breast cancer · Therapy Not Normalized
ALK fusion is flagged as manual review required because public trials show inclusion required evidence in 27 contexts. FDA CDx context should be reviewed manually.
Strongest role: Inclusion Required
Inclusion-required count: 23
Treatment-assignment count: 0
Stratification count: 0
Threshold count: 0
Common snippets: None extracted
Threshold label: Low
CDx label: Fda Cdx Context Manual Review Required
CDx maturity score: 2/5
Confidence: Low
Signal count: 0
Recent signals: 0
Density label: Low
https://clinicaltrials.gov/study/NCT01212887 | https://clinicaltrials.gov/study/NCT00940498 | https://clinicaltrials.gov/study/NCT01525966 | https://clinicaltrials.gov/study/NCT06556108 | https://clinicaltrials.gov/study/NCT04355858 | https://clinicaltrials.gov/study/NCT03499353 | https://clinicaltrials.gov/study/NCT03602079 | https://clinicaltrials.gov/study/NCT03065621 | https://clinicaltrials.gov/study/NCT03206203 | https://clinicaltrials.gov/study/NCT00834678 | https://clinicaltrials.gov/study/NCT00003953 | https://clinicaltrials.gov/study/NCT03007992 | https://clinicaltrials.gov/study/NCT01669252 | https://clinicaltrials.gov/study/NCT00636441 | https://clinicaltrials.gov/study/NCT00058526 | https://clinicaltrials.gov/study/NCT00877500 | https://clinicaltrials.gov/study/NCT01565499 | https://clinicaltrials.gov/study/NCT02876107 | https://clinicaltrials.gov/study/NCT02365805 | https://clinicaltrials.gov/study/NCT00432172 | https://clinicaltrials.gov/study/NCT00616967 | https://clinicaltrials.gov/study/NCT01693549 | https://clinicaltrials.gov/study/NCT07178938 | https://clinicaltrials.gov/study/NCT02856503 | https://clinicaltrials.gov/study/NCT01898117 | https://clinicaltrials.gov/study/NCT04770272 | https://clinicaltrials.gov/study/NCT04802876